icon
-
Press Release
Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria
-
Story
Going the extra mile to keep clinical trials on track during the COVID-19 pandemic -
Story
Putting patients first -
Story
Women in Science: Medy Attalla -
Story
Women in Science: Tania Small -
Story
Researchers aim to beat trick play by tumors with drug combo -
Story
Leveraging the liver’s ability to heal scarred tissue